Evidence map›Paper›PMID 34417899›Full record

ArticleEJNMMI research2021

Preselection of robust radiomic features does not improve outcome modelling in non-small cell lung cancer based on clinical routine FDG-PET imaging.

Carol Oliveira, Florian Amstutz, Diem Vuong, Marta Bogowicz, Martin Hüllner, Robert Foerster, Lucas Basler, Christina Schröder, Eric I Eboulet, Miklos Pless and 5 more

Abstract read
In one paragraph

Article in EJNMMI research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Impact of respiratory motion onJournal of applied clinical medical physics · 2023
    Article
  10. Review
  11. Article
  12. Article
  13. A review on advances inInsights into imaging · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Carol Oliveira *Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. carol.oliveira@kingstonhsc.ca.ORCID http://orcid.org/0000-0003-0174-5082
Florian Amstutz *Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Diem VuongDepartment of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Marta BogowiczDepartment of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Martin HüllnerDepartment of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Robert FoersterDepartment of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Lucas BaslerDepartment of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Christina SchröderDepartment of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Eric I EbouletSwiss Group for Clinical Cancer Research (SAKK) Coordinating Center, Bern, Switzerland.
Miklos PlessDepartment of Medical Oncology, Kantonsspital Winterthur, Winterthur, Switzerland.
Sandra ThiersteinSwiss Group for Clinical Cancer Research (SAKK) Coordinating Center, Bern, Switzerland.
Solange PetersDepartment of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
Sven HillingerDepartment of Thoracic Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Stephanie Tanadini-LangDepartment of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Matthias GuckenbergerDepartment of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Funding

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung 310030_173303
6 · The paper itself

Abstract

backgroundRadiomics is a promising tool for identifying imaging-based biomarkers. Radiomics-based models are often trained on single-institution datasets; however, multi-centre imaging datasets are preferred for external generalizability owing to the influence of inter-institutional scanning differences and acquisition settings. The study aim was to determine the value of preselection of robust radiomic features in routine clinical positron emission tomography (PET) images to predict clinical outcomes in locally advanced non-small cell lung cancer (NSCLC).

methodsA total of 1404 primary tumour radiomic features were extracted from pre-treatment [

resultsRobustness studies identified 179 stable features (13%), with 25% stable features for 3D versus 4D acquisition, 31% for attenuation correction and 78% for delineation. Univariable analysis found no significant robust features predicting 12-/24-month EFS and 12-month OS (p value > 0.076). Prognostic models without robust preselection performed well for 12-month EFS in training (AUC = 0.73) and validation (AUC = 0.74). Patient stratification into two risk groups based on 12-month EFS was significant for training (p value = 0.02) and validation cohorts (p value = 0.03).

conclusionsA PET-based radiomics model using a standardized, multi-centre dataset to predict EFS in locally advanced NSCLC was successfully established and validated with good performance. Prediction models with robust feature preselection were unsuccessful, indicating the need for a standardized imaging protocol.

Indexed as

Lung cancerMulti-centrePETRadiomicsRobust

Identifiers

PMID34417899
PMCPMC8380219

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.